Loading...
•
Mar 31, 2024
Cardiff Oncology Q1 2024 Earnings Report
Reported financial results for the first quarter ended March 31, 2024, and provided a business update.
Key Takeaways
Cardiff Oncology reported cash and equivalents of $67.2 million as of March 31, 2024, with a projected runway into Q3 2025. The company's net cash used in operating activities for the first quarter of 2024 was approximately $7.7 million. They also presented updated data at AACR Annual Meeting 2024 that supports ongoing first-line RAS-mutated mCRC clinical study.
Presented updated data at AACR Annual Meeting 2024 supporting the ongoing first-line RAS-mutated mCRC clinical study.
Announced first patient dosed for lead program in randomized first-line Phase 2 trial, CRDF-004, for patients with RAS-mutated mCRC.
Provided a clinical update on Phase 2 randomized second-line ONSEMBLE trial in mCRC, showing evidence of onvansertib’s role in improving the efficacy of SoC therapy in bev naïve patients.
Announced the publication of data from Phase 1b study in second line KRAS-mutated mCRC in the peer-reviewed journal Clinical Cancer Research.
Revenue by Segment
Forward Guidance
The Company has updated its expectation of the timing for an initial readout from the first-line RAS-mutated metastatic colorectal cancer (mCRC) randomized CRDF-004 trial to 2H 2024, based on the enrollment trends observed from active clinical trial sites
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...